IPO Timeline Raw facts
Company Overview
| Stock Name | Dualitybio-B |
|---|---|
| Stock Code | 09606 |
| Company Full Name | Duality Biotherapeutics, Inc. |
| Industry | 醫療保健 |
| Principal Activities | 公司是全球抗體偶聯藥物(「ADC」)領域的主要參與者,致力于為癌癥和自身免疫性疾病等患者研發ADC創新藥物。 |
| Listing Date | 2025-04-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區金谷路99號生物醫藥產業園三期B區項目3號樓301單元 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.dualitybiologics.com/ |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 94.60 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 100 shares |
| Entry Threshold | HK$ 9,460 |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | 17,332,300 shares |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 30.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 1,639,635,580 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 9,460 |
| 2 lots | 200 | HK$ 18,920 |
| 3 lots | 300 | HK$ 28,380 |
| 4 lots | 400 | HK$ 37,840 |
| 5 lots | 500 | HK$ 47,300 |
| 6 lots | 600 | HK$ 56,760 |
| 7 lots | 700 | HK$ 66,220 |
| 8 lots | 800 | HK$ 75,680 |
| 9 lots | 900 | HK$ 85,140 |
| 10 lots | 1,000 | HK$ 94,600 |
| 15 lots | 1,500 | HK$ 141,900 |
| 20 lots | 2,000 | HK$ 189,200 |
| 25 lots | 2,500 | HK$ 236,500 |
| 30 lots | 3,000 | HK$ 283,800 |
| 35 lots | 3,500 | HK$ 331,100 |
| 40 lots | 4,000 | HK$ 378,400 |
| 45 lots | 4,500 | HK$ 425,700 |
| 50 lots | 5,000 | HK$ 473,000 |
| 60 lots | 6,000 | HK$ 567,600 |
| 70 lots | 7,000 | HK$ 662,200 |
| 80 lots | 8,000 | HK$ 756,800 |
| 90 lots | 9,000 | HK$ 851,400 |
| 100 lots | 10,000 | HK$ 946,000 |
| 200 lots | 20,000 | HK$ 1,892,000 |
| 300 lots | 30,000 | HK$ 2,838,000 |
| 400 lots | 40,000 | HK$ 3,784,000 |
| 500 lots | 50,000 | HK$ 4,730,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 600 lots | 60,000 | HK$ 5,676,000 |
| 700 lots | 70,000 | HK$ 6,622,000 |
| 800 lots | 80,000 | HK$ 7,568,000 |
| 900 lots | 90,000 | HK$ 8,514,000 |
| 1,000 lots | 100,000 | HK$ 9,460,000 |
| 1,500 lots | 150,000 | HK$ 14,190,000 |
| 2,000 lots | 200,000 | HK$ 18,920,000 |
| 2,500 lots | 250,000 | HK$ 23,650,000 |
| 3,000 lots | 300,000 | HK$ 28,380,000 |
| 3,500 lots | 350,000 | HK$ 33,110,000 |
| 4,000 lots | 400,000 | HK$ 37,840,000 |
| 4,500 lots | 450,000 | HK$ 42,570,000 |
| 5,000 lots | 500,000 | HK$ 47,300,000 |
| 6,000 lots | 600,000 | HK$ 56,760,000 |
| 7,000 lots | 700,000 | HK$ 66,220,000 |
| 7,536 lots | 753,600 | HK$ 71,290,560 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 19.68B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | RMB 1,208.91 million |
| Listing Expenses | ~HK$ 120,300,000 |
| Listing Expenses / Funds Raised | ~8.1% |
| Total Pre-IPO Investment | approximately USD 137.5 million |
| First Day Close | HK$ 205.0 |
|---|---|
| First Day Open | HK$ 181.0 |
| First Day Change | 116.70% |
| First Day Volume | 10825200.0 |
| First Day Turnover | 2030240000.0 |
| Use of Proceeds | 1、約45.0%(或616.6百萬港元)將用于研究、開發及商業化公司的核心產品(即DB1303及DB-1311);
2、約30.0%(或411.1百萬港元)將用于研發公司的關鍵產品;
3、約15.0%(或205.5百萬港元)將用于為公司ADC技術平臺的持續開發提供資金,推進公司的其他管線資產以及探索及開發新藥物資產;
4、約10.0%(或137.0百萬港元)將用于運營資金及其他一般公司用途。 |
Underwriting Syndicate
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
凯易律师事务所 上海澄明则正律师事务所 君合律师事务所 Jun He Law Offices P.C. Harney Westwood & Riegels |
| Legal Advisor to Sponsors/Underwriters |
科律香港律师事务所 北京市通商律师事务所 |
| Auditor and Reporting Accountant | 罗兵咸永道会计师事务所 |
| Industry Advisor | 弗若斯特沙利文(北京)咨询有限公司上海分公司 |
| Compliance Advisor | 第一上海融资有限公司 CE AES612 |
| Receiving Banks | 招商永隆银行有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | BioNTech SE | 38,871,140 HKD | — | 2.37% | — | 6 months | 2025-10-15 |
| 2 | Emerging Markets Healthcare Partners LLC | 19,430,840 HKD | — | 1.19% | — | 6 months | 2025-10-15 |
| 3 | Lake Bleu Innovation Healthcare Master Fund Limited | 13,991,340 HKD | — | 0.85% | — | 6 months | 2025-10-15 |
| 4 | Lake Bleu Prime Healthcare Master Fund Limited | 24,879,800 HKD | — | 1.52% | — | 6 months | 2025-10-15 |
| 5 | LAV Star Opportunities Limited | 38,871,140 HKD | — | 2.37% | — | 6 months | 2025-10-15 |
| 6 | MY Asian Opportunities Master Fund, L.P. | 38,871,140 HKD | — | 2.37% | — | 6 months | 2025-10-15 |
| 7 | TruMed | 77,751,740 HKD | — | 4.74% | — | 6 months | 2025-10-15 |
| 8 | Worldwide Healthcare Partners LLC | 11,654,720 HKD | — | 0.71% | — | 6 months | 2025-10-15 |
| 9 | 富国基金管理有限公司 | 37,158,880 HKD | — | 2.27% | — | 6 months | 2025-10-15 |
| 10 | 富国资产管理(香港)有限公司 | 40,592,860 HKD | — | 2.48% | — | 6 months | 2025-10-15 |
| 11 | 汇添富基金管理股份有限公司 | 46,647,260 HKD | — | 2.84% | — | 6 months | 2025-10-15 |
| 12 | 盘京港景投资基金 | 38,871,140 HKD | — | 2.37% | — | 6 months | 2025-10-15 |
| 13 | 苏州苏创生物医药大健康创业投资基金合伙企业(有限合伙) | 15,542,780 HKD | — | 0.95% | — | 6 months | 2025-10-15 |
| 14 | 易方达基金管理有限公司 | 57,223,540 HKD | — | 3.49% | — | 6 months | 2025-10-15 |
| 15 | 易方达资产管理香港有限公司 | 4,975,960 HKD | — | 0.30% | — | 6 months | 2025-10-15 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 朱忠遠 | — |
| Company Secretary | 袁佳麗,曾穎雯 | — |
Major Shareholders
| Major Shareholders & Holdings | LAV USD(20.04%),King Star Med LP(7.92%),上海楹伽企業管理合伙企業(有限合伙)(7.68%),WuXi Biologics HealthCare Venture(5.01%) |
|---|
Market Sentiment
The IPO's oversubscription ratio of 115.14 signals intense retail demand. The hit rate of 92.34% is exceptionally high for such oversubscription, reflecting a 50% retail clawback under Mechanism A (old) that broadened allocations. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
No tier-level application data is available to assess the efficiency of specific subscription tiers. The high overall hit rate suggests limited tier-based discrimination in allocation, but without granular data, anomalies cannot be identified. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Demographic data shows 0 total holders with 0% Mainland and 0% Hong Kong participation, indicating missing or unreported statistics. Without reliable demographic figures, no patterns can be drawn. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)




